Incannex Healthcare INC 10-Q quarterly reports

Incannex Healthcare reports increased cash reserves and reduced R&D expenses for the quarter ended March 31, 2026, while continuing development of its drug candidates.

Incannex Healthcare reports increased cash reserves from financing activities, strategic shifts in R&D programs, and ongoing efforts to address a material weakness in internal controls for the quarter ended December 31, 2025.

Incannex Healthcare Inc. reported an increased net loss for Q1 2026 but significantly strengthened its cash position through recent financing activities.

Incannex Healthcare Inc. announces its financial results for the quarter ended March 31, 2025, highlighting advancements in its clinical-stage biopharmaceutical development programs despite ongoing losses.

Incannex Healthcare's Q2 2025 report reveals ongoing losses, efforts to secure funding, and adjustments to clinical trial strategies.

Incannex Healthcare's Q1 2025 report reveals a widened net loss and increased operating expenses, alongside new financing agreements to support ongoing clinical trials.

Incannex Healthcare Inc. saw a significant increase in research and development expenses during the quarter ended March 31, 2024, as it progresses with clinical trials.

Incannex Healthcare's latest quarterly report shows a significant increase in research and development expenses, offset by a substantial rise in R&D tax incentives.